New ebook: Drug discovery and the impact of mAbs

Monoclonal antibody

The low toxicity and high specificity of monoclonal antibodies (mAbs) continue to make them an appealing target for clinical research and investment. During 2023, 16 antibody therapeutics were granted approvals in the US or EU, either for the first time or for a new indication, covering uses as diverse as cancer, Alzheimer’s disease, diabetes and respiratory syncytial virus. With another 22 currently under review, it is likely we will see the potential applications for mAbs expand further in the coming years.

This eBook, sponsored by Thermo Fisher Scientific, explores the impact of monoclonal antibodies (mAbs) on the treatment of cancer, autoimmune and infectious diseases, and inflammatory conditions, as well as the latest clinical research and where the innovation in mAb development might be in the future.

Download this exclusive eBook to learn more about:

  • The range of applications for mAbs
  • The latest advances in protein and antibody engineering
  • Clinical innovation in mAb development
  • The future potential for therapeutic antibodies

Download now.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free